Fleming Asset Management will roll out its Luxembourg Global Life Sciences Fund on 14 April. The fun...
Fleming Asset Management will roll out its Luxembourg Global Life Sciences Fund on 14 April. The fund will be managed by Christopher Jones, who also runs Fleming Select American Smaller Companies, which has a biotechnology bias. He will be assisted by three analysts: John Regan, Marjan Daeipour and Craig Leighton. Jonathan Price, product manager for Fleming Asset Management in the US, said: "The project to map the human genome will be completed within six months, much earlier than was anticipated. There will be a massive revolution in healthcare as drugs will be able to target specific dis...
To continue reading this article...
Join Professional Adviser for free
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes